CN
菜单
R&D
R&D Pipeline

Building balanced and differentiated pipeline covering products from early- to late-stage through both in-house development and in-licensing.


.

Assets
Indication
Combo
Development area
Pre-clinical
Phase I
Phase II
Phase III
NDA
Commercial Rights
Utidelone Injection
Advanced breast cancer
Xeloda
CN
Global
Xeloda
Globa
Globa
Advanced non
Monotherapy
CN
Global
Monotherapy
Global
Global
Breast cancer neoadjuvant
AC
CN
Global
Solid tumors
Monotherapy／PD-1
CN
Global
Breast cancer brain metastasis
VEGF mAb
US
Global
Lung cancer brain metastasis
VEGF mAb
CN
Global
Glioblastoma
VEGF mAb
CN & US
Global
Utidelone Capsule
Solid tumors
Monotherapy
US
Global
Monotherapy／Xeloda
CN
Global
Advanced breast cancer
Xeloda
CN
Global
Advanced gastric and esophageal cancers
PD-1
CN & US
Global
Advanced liver cancer
PD-1
CN
Global
Advanced ovarian cancer
VEGF mAb
CN & US
Global
Advanced liver cancer
Solid tumors
TBD
CN
Global
Utidelone antibody-drug conjugate
drug conjugate
TBD
Global
Global
BG22
Solid tumors
TBD
Global
Global
BG18
Solid tumors
TBD
Global
Global
BG44
Solid tumors
TBD
Global
Global
Note:

Abbreviations: Xeloda: capecitabine; AC: anthracycline and cyclophosphamide; VEGF mAb: vascular endothelial growth factor monoclonal Antibody; TBD: to be determined.